These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 30773073)

  • 1. Overcoming challenges of venous thromboembolism in sickle cell disease treatment.
    Ogunsile FJ; Naik R; Lanzkron S
    Expert Rev Hematol; 2019 Mar; 12(3):173-182. PubMed ID: 30773073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know.
    Naik RP; Streiff MB; Lanzkron S
    J Thromb Thrombolysis; 2013 Apr; 35(3):352-8. PubMed ID: 23435703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of venous thromboembolism in patients with sickle cell disease undergoing noncardiovascular surgery.
    Osei SK; Long GW; Sharrak A; Derias N; Goodson R; Callahan RE; Studzinski DM; Brown OW
    J Vasc Surg Venous Lymphat Disord; 2023 May; 11(3):543-552. PubMed ID: 36574902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How I diagnose and treat venous thromboembolism in sickle cell disease.
    Shet AS; Wun T
    Blood; 2018 Oct; 132(17):1761-1769. PubMed ID: 29764840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venous thromboembolism in adults with sickle cell disease: experience of a single centre in the UK.
    van Hamel Parsons V; Gardner K; Patel R; Thein SL
    Ann Hematol; 2016 Jan; 95(2):227-32. PubMed ID: 26490882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venous thromboembolism in pediatric patients with sickle cell disease: A north American survey on experience and management approaches of pediatric hematologists.
    Betensky M; Kumar R; Hankins JS; Goldenberg NA;
    Thromb Res; 2022 Mar; 211():133-139. PubMed ID: 35151008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venous thromboembolism incidence in the Cooperative Study of Sickle Cell Disease.
    Naik RP; Streiff MB; Haywood C; Segal JB; Lanzkron S
    J Thromb Haemost; 2014 Dec; 12(12):2010-6. PubMed ID: 25280124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating thromboprophylaxis in the sickle cell disease population: Navigating the evidence gap.
    Davila J; O'Brien SH; Mitchell WB; Manwani D
    Br J Haematol; 2024 Jun; 204(6):2184-2193. PubMed ID: 38578212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality.
    Brunson A; Lei A; Rosenberg AS; White RH; Keegan T; Wun T
    Br J Haematol; 2017 Jul; 178(2):319-326. PubMed ID: 28369826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort study.
    Roberts MZ; Gaskill GE; Kanter-Washko J; Kyle TR; Jones BC; Bohm NM
    J Thromb Thrombolysis; 2018 May; 45(4):512-515. PubMed ID: 29556958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High incidence of venous thromboembolism recurrence in patients with sickle cell disease.
    Brunson A; Keegan T; Mahajan A; White R; Wun T
    Am J Hematol; 2019 Aug; 94(8):862-870. PubMed ID: 31074115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venous Thromboembolism in Children with Sickle Cell Disease: A Retrospective Cohort Study.
    Woods GM; Sharma R; Creary S; O'Brien S; Stanek J; Hor K; Young J; Dunn AL; Kumar R
    J Pediatr; 2018 Jun; 197():186-190.e1. PubMed ID: 29605397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and risk factors for venous thromboembolism in children with sickle cell disease: an administrative database study.
    Kumar R; Stanek J; Creary S; Dunn A; O'Brien SH
    Blood Adv; 2018 Feb; 2(3):285-291. PubMed ID: 29431623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex as an Independent Risk Factor for Venous Thromboembolism in Sickle Cell Disease: A Cross-Sectional Study.
    Roe AH; McAllister A; Kete C; Pishko A; Whitworth H; Schreiber CA; Sayani FA
    J Womens Health (Larchmt); 2022 Oct; 31(10):1467-1471. PubMed ID: 35675680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 and venous thromboembolism risk in patients with sickle cell disease.
    Singh A; Brandow AM; Wun T; Shet AS
    Blood Adv; 2022 Aug; 6(15):4408-4412. PubMed ID: 35763429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation strategies and recurrence of venous thromboembolic events in patients with sickle cell disease: a systematic review and meta-analysis.
    El-Amin N; Iness A; Cyrus JW; Sisler I; Karam O
    Ann Hematol; 2022 Sep; 101(9):1931-1940. PubMed ID: 35895101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary treatment of venous thromboembolic disease.
    Galanis T; Merli GJ
    Cardiol Clin; 2015 Feb; 33(1):49-57. PubMed ID: 25439330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enoxaparin adherence for venous thromboembolism prophylaxis in hospitalized patients with sickle cell disease.
    Sakon C; Nikirk M; O'Brien ARW
    Expert Rev Hematol; 2023 Feb; 16(2):147-150. PubMed ID: 36576324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for venous thromboembolism in children.
    Gerotziafas GT
    Int Angiol; 2004 Sep; 23(3):195-205. PubMed ID: 15765033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the management of venous thromboembolism.
    Bartholomew JR
    Cleve Clin J Med; 2017 Dec; 84(12 Suppl 3):39-46. PubMed ID: 29257737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.